Immix Biopharma (IMMX) Corporate presentation summary

Disease background and unmet need

• Approximately 38,500 U.S. patients suffer from relapsed/refractory AL amyloidosis, with no FDA-approved therapies available for this population.

• Existing standards of care yield only a 0-10% complete response rate, leaving most patients with poor outcomes and limited options.

• AL amyloidosis is caused by rogue plasma cells producing toxic light chains that damage organs, leading to heart, kidney, and liver failure.

• Most patients require second-line therapy within 12 months of frontline treatment, highlighting the urgent need for effective new therapies.

NXC-201 therapy and clinical platform

• NXC-201 is a sterically-optimized CAR-T therapy targeting BCMA on plasma cells, aiming to eliminate the source of toxic light chains.

• Proprietary design reduces non-specific activation and cytokine release, enhancing safety and cytotoxicity.

• NXC-201 demonstrated rapid normalization of disease markers and deep hematologic responses in clinical trials.

• The therapy is administered as a single IV infusion, with a median vein-to-vein time of 14 days.

Clinical trial results and efficacy

• In the NEXICART-2 U.S. phase 1/2 trial, NXC-201 achieved a 75% complete response rate in relapsed/refractory AL amyloidosis patients.

• Organ responses were observed in 70% of evaluable patients, including cardiac, renal, and liver improvements.

• Rapid normalization of light chains was seen within the first month for most patients.

• The complete response rate improved over time, with potential to reach 95% as more patients mature to response.